Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML)

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2019 Aug 28

PMID 31451539

Citations 11

Authors

Kelly Mitchell

Ulrich Steidl

Affiliations

Soon will be listed here.

Abstract

Therapies targeting cell-surface antigens in acute myeloid leukemia (AML) have been tested over the past 20 years with limited improvement in overall survival. Recent advances in the understanding of AML pathogenesis support therapeutic targeting of leukemia stem cells as the most promising avenue toward a cure. In this review, we provide an overview of the evolving leukemia stem cell (LSC) model, including evidence of the cell of origin, cellular and molecular disease architecture, and source of relapse in AML. In addition, we explore limitations of current targeted strategies utilized in AML and describe the various immunophenotypic antigens that have been proposed as LSC-directed therapeutic targets. We draw lessons from current approaches as well as from the (pre)-LSC model to suggest criteria that immunophenotypic targets should meet for more specific and effective elimination of disease-initiating clones, highlighting in detail a few targets that we suggest fit these criteria most completely.

Citing Articles

Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia.

Nair R, Salinas-Illarena A, Sponheimer M, Wullkopf I, Schreiber Y, Corte-Real J Clin Exp Med. 2024; 24(1):155.

PMID: 39003408 PMC: 11246277. DOI: 10.1007/s10238-024-01425-w.

Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells.

Murphy L, Winters A Biomedicines. 2023; 11(12).

PMID: 38137469 PMC: 10741170. DOI: 10.3390/biomedicines11123248.

Therapeutic targeting of leukemia stem cells in acute myeloid leukemia.

Barbosa K, Deshpande A Front Oncol. 2023; 13:1204895.

PMID: 37601659 PMC: 10437214. DOI: 10.3389/fonc.2023.1204895.

Zhang T, Liao D, Hu Y Transl Cancer Res. 2023; 12(5):1175-1195.

PMID: 37304546 PMC: 10248575. DOI: 10.21037/tcr-22-2526.

Association between Immunophenotypic Parameters and Molecular Alterations in Acute Myeloid Leukemia.

DE Pinho Pessoa F, Machado C, Barreto I, Sampaio G, DE Sousa Oliveira D, Ribeiro R Biomedicines. 2023; 11(4).

PMID: 37189716 PMC: 10135936. DOI: 10.3390/biomedicines11041098.

References

Jordan C, Upchurch D, Szilvassy S, Guzman M, Howard D, PETTIGREW A . The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-84. DOI: 10.1038/sj.leu.2401903. View

Esplin B, Shimazu T, Welner R, Garrett K, Nie L, Zhang Q . Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol. 2011; 186(9):5367-75. PMC: 3086167. DOI: 10.4049/jimmunol.1003438. View

Corces M, Chang H, Majeti R . Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. Front Oncol. 2017; 7:263. PMC: 5681525. DOI: 10.3389/fonc.2017.00263. View

Sun G, Wormsley S, Sparkes R, Naeim F, Gale R . Where does transformation occur in acute leukemia?. Leuk Res. 1991; 15(12):1183-9. DOI: 10.1016/0145-2126(91)90188-y. View

Flach J, Bakker S, Mohrin M, Conroy P, Pietras E, Reynaud D . Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature. 2014; 512(7513):198-202. PMC: 4456040. DOI: 10.1038/nature13619. View

Du W, Hu Y, Lu C, Li J, Liu W, He Y . Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia. Mol Clin Oncol. 2015; 3(4):833-838. PMC: 4487019. DOI: 10.3892/mco.2015.552. View

Wu S, Yang S, Zhu L, Wang Y, Zhang Y, Zhou J . Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy. Am J Med Sci. 2016; 351(5):473-9. DOI: 10.1016/j.amjms.2016.02.034. View

Yasuda T, Ueno T, Fukumura K, Yamato A, Ando M, Yamaguchi H . Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia. 2013; 28(2):426-8. DOI: 10.1038/leu.2013.278. View

Quek L, Otto G, Garnett C, Lhermitte L, Karamitros D, Stoilova B . Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med. 2016; 213(8):1513-35. PMC: 4986529. DOI: 10.1084/jem.20151775. View

10.

Hogge D, Shannon K, Kalousek D, Schonberg S, Schaffner V, Zoger S . Juvenile monosomy 7 syndrome: evidence that the disease originates in a pluripotent hemopoietic stem cell. Leuk Res. 1987; 11(8):705-9. DOI: 10.1016/0145-2126(87)90006-3. View

11.

Wei A, Tiong I . Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood. 2017; 130(23):2469-2474. DOI: 10.1182/blood-2017-08-784066. View

12.

Gentles A, Plevritis S, Majeti R, Alizadeh A . Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010; 304(24):2706-15. PMC: 4089862. DOI: 10.1001/jama.2010.1862. View

13.

Kristinsson S, Bjorkholm M, Hultcrantz M, Derolf A, Landgren O, Goldin L . Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011; 29(21):2897-903. PMC: 3138717. DOI: 10.1200/JCO.2011.34.8540. View

14.

Liesveld J, DiPersio J, Abboud C . Integrins and adhesive receptors in normal and leukemic CD34+ progenitor cells: potential regulatory checkpoints for cellular traffic. Leuk Lymphoma. 1994; 14(1-2):19-28. DOI: 10.3109/10428199409049647. View

15.

van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint A, Zweegman S . Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007; 21(8):1700-7. DOI: 10.1038/sj.leu.2404754. View

16.

Kotini A, Chang C, Chow A, Yuan H, Ho T, Wang T . Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell. 2017; 20(3):315-328.e7. PMC: 5337161. DOI: 10.1016/j.stem.2017.01.009. View

17.

Sato N, Caux C, Kitamura T, Watanabe Y, Arai K, Banchereau J . Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. Blood. 1993; 82(3):752-61. View

18.

Kim M, Yu K, Kenderian S, Ruella M, Chen S, Shin T . Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018; 173(6):1439-1453.e19. PMC: 6003425. DOI: 10.1016/j.cell.2018.05.013. View

19.

McGreal E, Ikewaki N, Akatsu H, Morgan B, Gasque P . Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol. 2002; 168(10):5222-32. DOI: 10.4049/jimmunol.168.10.5222. View

20.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View